statement
Immunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.
A statement by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.
한올바이오파마의 파트너사 이뮤노반트가 진행한 IMVT-1402의 난치성 류마티스 관절염(D2T RA) 임상 2b상에서 뛰어난 효능과 안전성이 입증되며 개발 전략의 타당성을 확보했다.
Discussion
Related claims
Following the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.report author · statementThis is the first case clinically demonstrating the strategic advantage IMVT-1402 has over Batoclimab.하나증권 제약/바이오 김선아 · statementIMVT-1402 is designed so its binding epitope does not compete with albumin, allowing high-dose continuous administration without hypercholesterolemia concerns, whereas Batoclimab requires dose reduction after several weeks.하나증권 제약/바이오 김선아 · statementIMVT-1402 is the first clinical case to demonstrate that continuous high-dose dosing is possible without the hypercholesterolemia concerns seen with Batoclimab.report author · statementIn the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.report author · statementIMVT-1402 value was calculated at approximately 3.7 trillion won.하나증권 제약/바이오 김선아 · statement